On April 18, 2023 Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome tumor immune evasion and drug resistance, reported that Dr. Amir Horowitz, Assistant Professor of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai will participate on behalf of the Company in a panel at Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023 to discuss our new acquired Tri-specific antibody (Press release, Purple Biotech, APR 18, 2023, View Source;id=261193&p=2265947&I=1206939-c7Z3G6f3m8 [SID1234630270]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date: Thursday, April 20, 2023
Time: 2:00-2:45 PM ET
Panel Title: New & better Approaches for Oncology Targets
A live webcast of the panel presentation will be available to registered attendees of the conference via the conference website.
Company management will be participating in virtual one-on-one investor meetings at the conference.